Targeting RNA Polymerase II to improve treatment for Acute Myeloid Leukemia
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11063044
This study is looking at how a new approach targeting a specific part of the cell's machinery can make current treatments for Acute Myeloid Leukemia (AML) work better, especially for patients whose cancer is tough to treat because of certain signals in their cells.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11063044 on ClinicalTrials.gov |
What this research studies
This research investigates how targeting RNA Polymerase II can enhance the effectiveness of existing treatments for Acute Myeloid Leukemia (AML), particularly in cases where the RAS signaling pathway is activated. The study aims to identify key components of the RNA Pol II pathway that contribute to resistance against FLT3 inhibitors, which are commonly used in AML treatment. By analyzing patient samples and pre-clinical models, researchers will evaluate the potential of RNA Pol II inhibitors to overcome this resistance and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Acute Myeloid Leukemia, especially those with mutations in the FLT3 gene or activated RAS signaling.
Not a fit: Patients with AML who do not have FLT3 mutations or RAS pathway activation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with AML, particularly those who have developed resistance to current therapies.
How similar studies have performed: Previous research has shown promise in targeting RNA Polymerase II in other cancer types, suggesting potential for success in this novel approach for AML.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SMITH, CATHERINE CHOY — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: SMITH, CATHERINE CHOY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.